Abstract:Background tPA (tissue‐type plasminogen activator) remains the only approved drug for acute ischemic stroke, with a potentially serious adverse effect: hemorrhagic transformation. The effects of antithrombotic agents on tPA‐induced hemorrhagic transformation after ischemic stroke are not clearly defined. We performed a systematic review and meta‐analysis in preclinical studies aiming to evaluate the efficacy of antithrombotic agents on tPA‐induced hemorrhagic transformation after ischemic stroke. Methods and Results We conducted a systematic review and meta‐analysis of studies testing antithrombotic agents in animal models of tPA‐induced hemorrhagic transformation. The pooled effects were calculated using random‐effects models, and heterogeneity was explored through meta‐regression and subgroup analyses. Publication bias was assessed using trim and fill method and the Egger test. The efficacy of 18 distinct interventions was described in 22 publications. The pooled data showed a significant improvement in cerebral hemorrhage, infarct size, and neurobehavioral outcome in treated compared with control animals (standardized mean difference, 0.45 [95% CI, 0.11–0.78]; standardized mean difference, 1.18 [95% CI, 0.73–1.64]; and standardized mean difference, 0.91 [95% CI, 0.49–1.32], respectively). Subgroup analysis indicated that quality score, random allocation, control of temperature, anesthetic used, stroke model used, route of drug delivery, time of drug administration, and time of assessment were significant factors that influenced the effects of interventions. Conclusions Administration with antiplatelet agents revealed statistically significant improvement in all the outcomes. Anticoagulant agents showed significant effects in infarct size and neurobehavioral score, but fibrinolytic agents did not show any significant improvement in all the outcomes. The conclusions should be interpreted cautiously given the heterogeneity and publication bias identified in this analysis. Nonstandard Abbreviations and Acronyms HT hemorrhagic transformation RESTART Restart or Stop Antithrombotics Randomized Trial RETRACE German‐Wide Multicenter Analysis of Oral Anticoagulation Associated Intracerebral Hemorrhage SMD standardized mean difference Clinical Perspective What Is New? Antithrombotic therapy resulted in significant improvement of cerebral hemorrhage, infarct size, and neurobehavioral score in animal models of tPA (tissue‐type plasminogen activator)–induced hemorrhagic transformation. Study quality score, random allocation, control of temperature, anesthetic used, stroke model, route of drug delivery, time of drug administration, and time of assessment were significant factors that influenced the effects of antithrombotic agents. What Are the Clinical Implications? Our results revealed that antiplatelet agents and anticoagulant agents were the more effective subtypes of antithrombotic agents, whereas fibrinolytic agents produced no significant differences. Results of this analysis provided guidance for future animal studies investigating the efficacy of antithrombotic agents on tPA‐induced hemorrhagic transformation and valuable insight into clinical drug use and trial design. Early intravenous thrombolysis with tPA (tissue‐type plasminogen activator) remains the only US Food and Drug Administration approved agent for acute ischemic stroke treatment. However, tPA can lead to an increased risk of hemorrhagic transformation (HT), especially beyond 4.5 hours of stroke onset. 1 HT is often associated with significant mortality and disability rate. 2 Therefore, it is important to control the risk of HT when tPA is used in patients after acute ischemic stroke. Antithrombotic agents are widely used to prevent and treat thrombosis in the venous and arterial circulations. 3 After acute ischemic stroke, antithrombotic therapy is recommended to prevent recurrent thromboembolism.<a class="tab-link" hre -Abstract Truncated-

tPA Helpers in the Treatment of Acute Ischemic Stroke: Are They Ready for Clinical Use?

Adjunctive Therapy Approaches for Ischemic Stroke: Innovations to Expand Time Window of Treatment

Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders

Early Ischemic Blood Brain Barrier Damage: A Potential Indicator for Hemorrhagic Transformation Following Tissue Plasminogen Activator (tpa) Thrombolysis?

Antithrombotic Agents for tPA-Induced Cerebral Hemorrhage: A Systematic Review and Meta-Analysis of Preclinical Studies.

Neurovascular Inflammation and Complications of Thrombolysis Therapy in Stroke

The paradox of tPA in ischemic stroke: tPA knockdown following recanalization improves functional and histological outcomes

Optimal Delay Time of CT Perfusion for Predicting Cerebral Parenchymal Hematoma After Intra-Arterial tPA Treatment.

Angioedema and Hemorrhage After 4.5-Hour tPA (Tissue-Type Plasminogen Activator) Thrombolysis Ameliorated by T541 via Restoring Brain Microvascular Integrity

Systemic Thrombolysis With Recombinant Tissue Plasminogen Activator and Tirofiban in Acute Middle Cerebral Artery Occlusion

Ancillary approaches to plasminogen activators

Tissue Plasminogen Activator in Acute Cardiac Arrest

Intravenous thrombolysis for acute ischemic stroke: a bridge between two centuries

tPA Mobilizes Immune Cells that Exacerbate Hemorrhagic Transformation in Stroke

Single- and two- chain tissue type plasminogen activator treatments differentially influence cerebral recovery after stroke

The Next Step in the Treatment of Stroke

What is the Role for Intra-Arterial Therapy in Acute Stroke Intervention?

Intra-arterial neuroprotective therapy as an adjunct to endovascular intervention in acute ischemic stroke: A review of the literature and future directions

[t-PA in thrombolytic therapy of acute myocardial infarct]

Molecular Insights and Therapeutic Targets for Blood–brain Barrier Disruption in Ischemic Stroke: Critical Role of Matrix Metalloproteinases and Tissue-Type Plasminogen Activator

Thrombolysis in Neuromedicine